A  team of researchers from Cleveland Clinic share insights from an early set of 19,000 patients to receive immune checkpoint inhibitor treatments for colorectal cancer in the US.   The report comes ...

Colorectal cancer is a serious but preventable disease if detected early. Advances in diagnostics, such as biomarker analysis ...

The results showed immune checkpoint inhibitors greatly improved survival rates for patients living with metastatic MSI-H colorectal cancer, in line with clinical trials. Investigators also found ...

Patients with MSI-H mCRC had a higher probability of survival with first-line ICI therapy than with chemotherapy, but second-line or later ICIs did not confer the same benefit.

Real world data show that immunotherapy leads to better overall survival outcomes than chemotherapy in patients with ...

D'Souza. "About 6% of metastatic colon cancer patients have MSI-high, but their outcomes and response to immunotherapy is exceptional." After multiple surgeries, radiation and immunotherapy ...

Solnerstotug continues to be well tolerated, with no dose-limiting toxicities and the majority of AEs Grade 1 or 2 in severity. Out of 60 patients, there have been four (7%) cases of Grade 1 cytokine ...